Dr. Yiyin Tang 唐一吟
Chief Physician
Department of Breast Surgery, Yunnan Cancer Hospital, Kunming
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment of breast diseases, including breast cancer surgery, oncoplastic reconstruction (implant and autologous tissue), correction of deformities, endoscopic surgery, and cosmetic procedures such as reduction mammoplasty.
Dr. Tang is Chief Physician and Administrative Deputy Director of the Second Breast Surgery Department at Yunnan Cancer Hospital. Dr. Tang holds a bachelor’s degree from Kunming Medical University (1998) and a master’s in hospital management from Nankai University and Flinders University (2014). Dr. Tang trained at the Breast Center of the Plastic Surgery Hospital, Chinese Academy of Medical Sciences in 2008.
Professional roles
- Standing Committee Member, 2nd Plastic and Aesthetic Surgery Professional Committee, Chinese Medical Doctor Association
- Member, Breast Disease Professional Committee, China Medicine Education Association
- Standing Committee Member, Breast Cancer Professional Committee, Yunnan Preventive Medicine Association
- Standing Committee Member, Breast Cancer Professional Committee, Yunnan Medical Doctor Association
Name order: in Chinese the family name comes first (Tang Yiyin). Papers usually list the name as Yiyin Tang or Tang Y.
Selected publications
21 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- Aesthetic Plast Surg, 2025 (senior author): Advances in Etiology and Prevention of Capsular Contracture After Breast Implantation. PubMed 39586860
- Clin Breast Cancer, 2022 (senior author): The Interaction of NTN4 and miR-17-92 Polymorphisms on Breast Cancer Susceptibility in a Chinese Population. PubMed 35232666
- Int J Mol Med, 2019 (first author): Epigenetically altered miR‑193a‑3p promotes HER2 positive breast cancer aggressiveness by targeting GRB7. PubMed 31017268
- Clin Breast Cancer, 2019 (first author): A Genetic Variant of rs145204276 in the Promoter Region of Long Noncoding RNA GAS5 Is Associated With a Reduced Risk of Breast Cancer. PubMed 30846409
- Oncol Lett, 2018 (senior author): Tunicamycin suppresses breast cancer cell growth and metastasis via regulation of the protein kinase B/nuclear factor-κB signaling pathway. PubMed 29541178
- DNA Cell Biol, 2017 (first author): Circular RNA hsa_circ_0001982 Promotes Breast Cancer Cell Carcinogenesis Through Decreasing miR-143. PubMed 28933584
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion